Director Tong Chunrong's Team:

Sequential CD19-22 CAR-T Therapy for Post-Transplant Relapsed B-ALL

The team utilized sequential CD19 and CD22 CAR-T cell therapy for patients with post-transplant relapsed B-ALL expressing both CD19 and CD22 antigens.After the first CD19 CAR-T infusion,23 out of 27 patients(85%)achieved complete remission(CR);21 out of these 27 patients received a second CD22 CAR-T treatment,followed by a median follow-up of 19.7 months(range 5.6-27.3 months),with 14 patients still in CR.The overall survival(OS)rate and event-free survival(EFS)rate at 12 and 18 months were 88.5%and 67.5%,respectively.

Director Pan Jing's Team:

Sequential CD19 followed by CD22 CAR-T Treatment for Children with R/R B-ALL

The sequential CD19 followed by CD22 CAR-T treatment for children with refractory/relapsed acute T-cell leukemia employs a dual-target sequential strategy,achieving an optimal balance between efficacy and toxicity.Compared to single-target CAR-T therapy,this strategy significantly reduced the overall relapse rate and antigen-negative relapse rate,with 18-month event-free survival(EFS)and overall survival(OS)rates of 79%and 96%,respectively,bringing new hope to breakthroughs in this field.